WATS3D News, Media and Press Releases
CDx Diagnostics Announces Appointment of New CFO and Executive Vice President of Managed Care
CDx Diagnostics, an innovator in computer synthesized 3D tissue analysis for the early detection and surveillance of Barrett’s esophagus, today announced the expansion of its leadership team with the appointment of two seasoned industry leaders.
Nasdaq GlobeNewswire, March 6, 2018
ASGE Tech Talks™: The Role of Wide-Area Transepithelial Sampling (WATS) Procedure in the Screening for and Surveillance of Barrett’s Esophagus
ASGE Tech Talks™, January 3, 2018
Increased detection of Barrett’s esophagus and esophageal dysplasia with adjunctive use of wide-area transepithelial sample with three-dimensional computer-assisted analysis (WATS)
Barrett’s esophagus (BE) and esophageal dysplasia (ED) are frequently missed during screening and surveillance esophagoscopy because of sampling error associated with four-quadrant random forceps biopsy (FB).
Adjunctive use of WATS to FB significantly improves the detection of both BE (83%) and ED (88.5%). Sampling error, an inherent limitation associated with screening and surveillance, can be improved with WATS allowing better informed decisions to be made about the management and subsequent treatment of these patients.
UEG Journal, November 6, 2017
WATS3D Shown to be over 4X More Effective in Detecting High-Grade Dysplasia and Esophageal Adenocarcinoma
CDx Diagnostics, developer of the WATS3D biopsy, or Wide Area Transepithelial Sampling with 3D Tissue Analysis for the detection and surveillance of Barrett’s esophagus today announced the publication of new, pivotal, multicenter, crossover data in the latest issue of Gastrointestinal Endoscopy. The study found that WATS3D increased the detection of High-Grade Dysplasia and Esophageal Adenocarcinoma (HGD/EAC) by more than 400% compared to the standard Seattle protocol random forceps biopsy, even when those random biopsies are carefully performed in academic centers by some of the world’s most experienced endoscopists.
Marketwired, August 8, 2017
Galen Partners Completes Majority Recapitalization of CDx Diagnostics
Leading healthcare-focused growth equity firm and operating partners collaborate with existing management to acquire a proprietary cancer diagnostics company
Nasdaq GlobeNewswire, July 11, 2017
Promising Technologies Arise for Diagnosis of Barrett’s Esophagus
Article: Discussion of recent and prospective advancements in diagnosing cancer in Barrett’s esophagus which may allow for earlier and better detection..
Healio Gastroenterology, February 2017
Endoscopy Insights From Prateek Sharma, MD
Article: From wide-area transepithelial sampling in Barrett’s esophagus to endoscopic submucosal dissection for colorectal cancer, Prateek Sharma, MD, professor of medicine at the University of Kansas School of Medicine, in Kansas City, reviews his favorite scope-related abstracts from the 2016 Digestive Disease Week.
Gastroenterology & Endoscopy News, December 2016
The Role of Brush Biopsy in the Management
Article discussing better tissue assessment provided by WATS3D, the relevance of crypt dysplasia, and how improved surveillance procedures can may help determine which patients without confirmed low- or high-grade dysplasia are most likely to progress before their next surveillance procedure.
Gastroenterology & Hepatology Volume 12, Issue 11, November, 2016
Biopsy Combo Boosts Esophageal Cancer Detection
– Brush plus standard biopsy shows promise in Barrett’s esophagus
MedPage Today, May 24, 2016
New Data Demonstrate That WATS3D Is 4X More Effective Than the Seattle Random Biopsy Protocol in the Detection of High-Grade Dysplasia and Esophageal Adenocarcinoma
Results From a Pivotal Prospective Randomized Crossover Study Conducted at 14 Major Academic Gastroenterology Centers Presented at Digestive Disease Week
May 21, 2016
New Data Presented at UEG Week Shows Use of WATS3D Significantly Increases Detection of Esophageal Pre-Cancer
Compared to Standard Forceps Biopsy Alone, WATS3D Enhanced the Detection Rate of Barrett’s Esophagus by 83.0% and Dysplasia by 88.5% in Multi-Center Community-Based Study
October 27, 2015
CDx Diagnostics to Present New Data Demonstrating Increased Detection of Esophageal Pre-Cancer Using WATS3D
Results From Large Prospective Multi-Center Community-Based Study of More Than 12,000 Patients to Be Presented at the ACG 2015 Annual Scientific Meeting
October 14, 2015
WATS3D Three Dimensional Computer-Assisted Biopsy Analysis Demonstrates Exceptionally High Inter-Observer Agreement in the Evaluation of Esophageal Pre-Cancer
New Study Results Published in the American Journal of Gastroenterology
September 10, 2015
WATS3D Biopsy Increases Detection of Barrett’s Esophagus by 68.4% and Esophageal Dysplasia by 64.7% in Largest Study to Date
Results of a Study of Over 2,500 Patients Who Received EGD in Community-Based Settings Highlighted in the Presidential Plenary Session at Digestive Disease Week
May 05, 2014
New Study Confirms High Inter-Observer Agreement Using the WATS3D Biopsy for Evaluation of Esophageal Pre-Cancer
Provides Powerful Validation for the Clinical Value of Using the WATS3D Procedure as a Complement to Four Quadrant Biopsy; Results Highlighted in an Oral Presentation at Digestive Disease Week
May 04, 2014
Study Shows WATS3D Biopsy Increases Detection of Pre-Cancer in the Esophagus by 50% in Post-Ablation Patients
Data Underscores Value of Using WATS3D as a Surveillance Tool for Residual or Recurrent Pre-Cancer
October 14, 2013
CDx Diagnostics to Highlight Groundbreaking New WATS3D Data at the American College of Gastroenterology Annual Scientific Meeting
First Study Evaluating the WATS3D Biopsy for the Detection of Biliary Tract Cancer | Two Studies Reinforcing the Value of WATS3D for Surveillance of Esophageal Pre-Cancer
October 10, 2013
New Data Reinforce the Value of the CDx Diagnostics’ WATS3D Biopsy in Detecting Otherwise Hidden Precancer of the Esophagus
Multicenter Study Confirms Earlier Research Showing That a Unique “Wide Area Biopsy” Analyzed by 3D Imaging Algorithms Originally Developed for Missile Defense, Can Help to Defend Patients Against Undetected Precancerous Disease
May 19, 2013
Two New Studies Show CDx Diagnostics’ WATS3D Esophageal Biopsy Increases Detection of Residual and Recurrent Barrett’s Esophagus and Dysplasia in Post-Ablation Patients
Adjunctive Use of WATS3D Improves Detection of Residual Barrett’s Esophagus Missed by Random Forceps Biopsy Surveillance
May 20, 2013
Oral Cancer Prevention International and CDx Laboratories Merge to Form CDx Diagnostics
New Company to Market Innovative Diagnostic Tools That Enable Prevention and Earlier Detection of Oral, Laryngeal and Esophageal Cancers Strong Pipeline of New Tests for Liver, Pancreatic and Colon Cancer Will Create Additional Value
January 8, 2013
New Data Confirm Value of CDx Diagnostics’ WATS3D Biopsy in Detecting Residual Precancerous Tissue Following Ablation for Barrett’s Esophagus
Data Presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting
Oct 22, 2012
CDx Diagnostics Announces Live Demonstration Series of the New WATS3D Biopsy at DDW 2012
Computer-Aided Diagnostic System Shown to Increase Detection of Barrett’s and Dysplasia by up to 40%
May 17, 2012
Improved Endoscopy Method Increases Detection of Esophageal Pre-Cancer by Over 40 Percent
Studies Confirm an Important Advance Against the Most Rapidly Growing Cancer in the U.S.
May 19, 2011
Brush Biopsy Plus Forceps Biopsy Increase Detection of Barrett’s Esophagus and Dysplasia, Two Studies Report
Gastroenterology & Endoscopy News, May 2011
New Method for Detection of Precancerous Cells in Heartburn Patients Can Help to Prevent Esophageal Adenocarcinoma, the Most Rapidly Growing Form of Cancer in the U.S.
March 24, 2011